PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33775687-8 2021 In the follow-up caspase activation assays, docetaxel was confirmed to be a victim of CYP3A4-mediated resistance, which is, at least partly, brought by impaired activation of caspases 3/7, 8 and 9. Docetaxel 44-53 caspase 3 Homo sapiens 175-196 34787067-8 2021 We also found that Zafirlukast ameliorated Docetaxel-induced apoptosis by reducing Caspase-3 and Caspase-9 activity. Docetaxel 43-52 caspase 3 Homo sapiens 83-92 32371266-8 2020 DTX loaded crosslinked MLNPs showed the highest efficacy against 3D spheroids of TNBC, in addition the MLNPs also induced higher levels of apoptosis, as assessed by annexin V/PI assays and increased caspase 3/7 activity in MDA-MB-231 cells in comparison to cells treated with DTX-loaded un-crosslinked MLNP (used as a control) and free DTX. Docetaxel 0-3 caspase 3 Homo sapiens 199-210 32578137-7 2021 The results of plate reader assay and laser confocal microscopy image analyses indicated a protective role of MT and Se on the DT-induced increase of mitochondrial ROS, cytosolic ROS, apoptosis, lipid peroxidation, intracellular free Zn2+, Ca2+, and caspase-3 and -9 levels in the DRG and SH-SY5Y cells. Docetaxel 127-129 caspase 3 Homo sapiens 250-266 33408886-9 2020 Poly (ADP-ribose) polymerase cleavage and caspase 3/7 activity were increased in docetaxel-treated tumor cells with WARS overexpression. Docetaxel 81-90 caspase 3 Homo sapiens 42-53 32994029-8 2020 The results of the cellular uptake studies showed a significantly higher untake of the LHRH targeted NCs, while the LHRH-targeted-PEGylated DTX: QU NCs exhibited higher caspase-3 activity. Docetaxel 140-143 caspase 3 Homo sapiens 169-178 31540423-5 2019 Moreover, the combined drugs (DTX+TQ) with inhibitors of PI3K/AKT increased the expression of pro-apoptotic markers (BAX and BID) along with caspase-3, PARP and decreased expression of the anti-apoptotic marker, BCL-XL. Docetaxel 30-33 caspase 3 Homo sapiens 141-150 30880686-10 2019 In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. Docetaxel 119-128 caspase 3 Homo sapiens 233-242 27840955-4 2017 Downregulation of miR-141 suppressed cell proliferation, induced cell death and increased caspase-3 activity in H1299 or H2009/docetaxel cells. Docetaxel 127-136 caspase 3 Homo sapiens 90-99 30555232-14 2018 DTX-loaded FA/PLGA NPs showed the highest apoptotic effect through the activation of Caspase-9, Caspase-3, and TP53 genes by 2.8-, 1.6-, and 1.86-fold, respectively. Docetaxel 0-3 caspase 3 Homo sapiens 96-105 30061946-10 2018 PI3K/AKT inhibitor LY294002 restored DTX-induced caspase-3 activation and Bcl-2 phosphorylation, reversed the effect of CCL2 on the viability of A549 cells and enhanced DTX-induced cytotoxicity. Docetaxel 37-40 caspase 3 Homo sapiens 49-58 29301832-12 2018 Coupling docetaxel with NOS inhibition increased EnR-stress response via coactivation of ATF4 and CHOP, which triggered the pASK1/JNK proapoptotic pathway, promoting cleavage of caspases 3 and 9.Conclusions: iNOS is a critical target for docetaxel resistance in TNBC. Docetaxel 9-18 caspase 3 Homo sapiens 178-194 28440463-11 2017 Consistent with this, Livin-knockdown cells showed greater expression of cleaved caspases-3 and -7 and poly(ADP-ribose)polymerase compared with that in control cells after cisplatin, 5-FU, or docetaxel treatment. Docetaxel 192-201 caspase 3 Homo sapiens 81-98 27840955-6 2017 Conversely, up-regulation of miR-141 promoted cell proliferation, inhibited cell death and caspase-3 activity in H1299 or H2009/docetaxel cell. Docetaxel 128-137 caspase 3 Homo sapiens 91-100 31470686-3 2019 For this purpose, the impact on the level of reactive oxygen species, the mitochondrial membrane potential, cell cycle distribution and the activity of caspases-3/7, -8 and -9 of PAMAM-doc-trastuzumab and PAMAM-ptx-trastuzumab conjugates was determined and compared with free docetaxel and paclitaxel toward HER-2-positive (SKBR-3) and negative (MCF-7) human breast cancer cell lines. Docetaxel 185-188 caspase 3 Homo sapiens 152-175 30519344-6 2018 In vivo, ZD55-IL-24 and DTX synergistically inhibited the growth and activated the apoptosis of DU145 xenografts, accompanied by significantly decreased PARP-1 levels and increased caspase-3 and caspase-8 levels as well as decreased CD31 expression. Docetaxel 24-27 caspase 3 Homo sapiens 181-190 28981599-7 2017 Moreover, DKK4-knockdown promoted the pro-apoptotic effect of docetaxel characterized with caspase 3 activation and inhibition of BCL-2 expression in A549/DTX cells, which was possibly mediated by inducing the activation of c-Jun N-terminal kinase (JNK)-related signaling pathway. Docetaxel 62-71 caspase 3 Homo sapiens 91-100 28799743-7 2017 Moreover, GNP-DTX/Qu/IMA demonstrated obvious advantages in inducing apoptosis and mediating the expression of apoptosis-related proteins (Caspase 3, Caspase 9, and bcl-2). Docetaxel 14-17 caspase 3 Homo sapiens 139-148 27153245-11 2016 Docetaxel induced significant levels of Caspase-3 and PARP cleavage in PCa cells, while GAS6 protected PCa cells from docetaxel-induced apoptotic signaling. Docetaxel 0-9 caspase 3 Homo sapiens 40-49 27035282-5 2016 Docetaxel-induced cell death was analyzed using flow cytometric and caspase-3 assays. Docetaxel 0-9 caspase 3 Homo sapiens 68-77 27686228-10 2016 UCA1 siRNA, Sirt1 siRNA and miR-204 mimics could enhance docetaxel-induced activation of caspase-3 and cell apoptosis in 22RV1/DR cells. Docetaxel 57-66 caspase 3 Homo sapiens 89-98 27082738-9 2016 Interestingly, docetaxel hardly induced caspase-3/7 activation in control or Bcl-2-overexpressing DU145 cells, but did at a low level in LNCaP cells, another prostate cancer cell line. Docetaxel 15-24 caspase 3 Homo sapiens 40-49 27340870-6 2016 In addition, we found that p38 MAPK and caspase-3 inhibitors can reduce the enhanced apoptosis levels of MHCC97-H cells resulted by either ST6Gal-I silencing or docetaxel treatment. Docetaxel 161-170 caspase 3 Homo sapiens 40-49 27035282-7 2016 Treatment with docetaxel inhibited cell growth, promoted cytotoxicity, activated apoptosis and increased caspase-3 activity in the LNCaP cells. Docetaxel 15-24 caspase 3 Homo sapiens 105-114 25634538-7 2015 DTX upregulated caspase-3 activity and TUNEL-positive cells. Docetaxel 0-3 caspase 3 Homo sapiens 16-25 25708950-8 2015 Pre-treatment with the autophagy inhibitor, 3-methyladenine (5 mM) significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. Docetaxel 110-119 caspase 3 Homo sapiens 241-250 25138252-6 2014 Moreover, the co-delivery system of DTX and siRNA exhibited a remarkable apoptosis of cancer cells with elevated levels of caspase 3/7 activity (apoptosis markers). Docetaxel 36-39 caspase 3 Homo sapiens 123-132 24839986-8 2014 Induced expression of caspase-3 was evident in the PC-3R2IIIb cells and was further enhanced by treatment with docetaxel. Docetaxel 111-120 caspase 3 Homo sapiens 22-31 24839986-12 2014 This together with enhancement of apoptotic pathways involving caspase-3 may enhance chemosensitivity particularly to docetaxel which is widely used in the treatment of castration-resistant prostate cancer. Docetaxel 118-127 caspase 3 Homo sapiens 63-72 24155950-7 2013 Moreover, we found that other mitotic inhibitors (Vincristine and Docetaxel), in combination with bortezomib, also suppress the Bcr-Abl-induced pro-survival signals and result in caspase 3 activation. Docetaxel 66-75 caspase 3 Homo sapiens 179-188 19369859-8 2009 Caspase-3 activation by docetaxel was enhanced after addition of cetuximab in OVCAR-3 and after addition of cetuximab plus pertuzumab in IGROV-1 and SKOV-3. Docetaxel 24-33 caspase 3 Homo sapiens 0-9 22858003-6 2012 Docetaxel, the drug of choice for the treatment of PCa, produced a concentration-dependent activation of caspase-3, an increase in cell death assessed by lactate dehydrogenase release to the culture medium, cell cycle arrest and inhibition of tumor cell proliferation. Docetaxel 0-9 caspase 3 Homo sapiens 105-114 22490358-12 2012 CONCLUSIONS: The combination of ABT-737 with docetaxel can synergistically inhibit the proliferation of PC-3 cells through inducing apoptosis, which may be associated with cell cycle arrest, down-regulation of Bcl-2, Bcl-xL and Mcl-1 expression and activation of caspase-3. Docetaxel 45-54 caspase 3 Homo sapiens 263-272 20878124-3 2010 Herein we show that docetaxel induces dose-dependent apoptosis in non-small cell lung cancer A549 cells, as detected by Annexin-V positive cells and PARP cleavage, which is via mitochondrial pathway and dependent on caspase-3 activation. Docetaxel 20-29 caspase 3 Homo sapiens 216-225 20057500-6 2010 Significantly more light was detected at 24 (P<0.05), 48 (P<0.01), and 72 h (P<0.01) in the docetaxel-treated group compared with the vehicle-treated group, with caspase-3 activation at these time points confirmed using immunohistochemistry. Docetaxel 101-110 caspase 3 Homo sapiens 171-180 20044612-7 2009 Gefitinib alone and combined with docetaxel induced internucleosomal DNA fragmentation and caspase-3 activation in human promyelocytic leukemia HL-60 cells, but not in HSC-2 or T98G cells. Docetaxel 34-43 caspase 3 Homo sapiens 91-100 24432379-3 2013 The combination of YM155 with docetaxel showed synergistic antiproliferative and caspase 3/7-inducing effects in MRK-nu-1 and MDA-MB-453 human TNBC cell lines in vitro. Docetaxel 30-39 caspase 3 Homo sapiens 81-90 23138939-12 2013 Finally, apoptosis was also clearly observed as demonstrated by the cleavage of poly(ADP-ribose) polymerase (PARP) and nuclear fragmentation through the activation of caspase-3 by combined treatment with docetaxel and gamma-tocotrienol. Docetaxel 204-213 caspase 3 Homo sapiens 167-176 22994780-7 2012 Treatment with TSA/TXT or TSA/erlotinib led to a significant increase of cleaved caspase-3 expression, also resulting in elevated acetylation of alpha-tubulin or hsp90 and decreased expression of EGFR, which was negatively associated with the level of acetylated hsp90. Docetaxel 19-22 caspase 3 Homo sapiens 81-90 21273177-3 2011 The reverse sequence of docetaxel before bortezomib was associated with increased apoptosis, cleavage of caspase-3 and PARP (poly [ADP-ribose] polymerase), and reduction in Bcl-2. Docetaxel 24-33 caspase 3 Homo sapiens 105-114 19490758-7 2009 Imatinib and docetaxel induced apoptosis through caspase-3 enzyme activity and mitochondrial membrane potential. Docetaxel 13-22 caspase 3 Homo sapiens 49-58 16536899-6 2006 Induction of apoptosis in A549 cells by DOC (non-aerosolized and aerosolized) in combination with CXB was evaluated by established techniques, such as caspase-3 estimation and terminal deoxynucleotidyl transferase-mediated nick end labelling (TUNEL) staining. Docetaxel 40-43 caspase 3 Homo sapiens 151-160 18957056-10 2008 Caspase 3 activation was low after docetaxel, suggestive of caspase-independent mechanisms of cell death. Docetaxel 35-44 caspase 3 Homo sapiens 0-9 18190795-9 2008 Concurrently, Bcl-2 expression was upregulated, and taxotere-induced activation of procaspase 3 was inhibited after PLD"s transfection. Docetaxel 52-60 caspase 3 Homo sapiens 83-95 18006775-7 2007 In vitro, docetaxel alone induced both caspase-3/7 activity as well as poly(ADP)ribose polymerase and caspase-7 cleavage in U-87 MG cells; these events were enhanced when used in combination with AMG 102. Docetaxel 10-19 caspase 3 Homo sapiens 39-48 18186959-5 2007 Docetaxel treatment led to apoptosis as assessed by increased sub-G1 DNA content and cleavage of caspase 3 and poly (ADP-ribose) polymerase. Docetaxel 0-9 caspase 3 Homo sapiens 97-139 19147759-9 2009 In vivo, docetaxel + DIM-C-pPhC(6)H(5) reduced lung weights by 57% compared with 39% by docetaxel or 22% by DIM-C-pPhC(6)H(5) alone, induced apoptosis in 43% of the tumor cells compared with 29% and 22% in tumors treated with docetaxel and DIM-C-pPhC(6)H(5), respectively, and increased procaspase-3 cleavage compared with either agent alone. Docetaxel 9-18 caspase 3 Homo sapiens 287-299 16536899-10 2006 The specific caspase-3 activity in A549 cells treated with DOC (0.01 microg mL(-1)) and CXB (10.0 microg mL(-1)) combination was 4 times higher than CXB and untreated control group, respectively. Docetaxel 59-62 caspase 3 Homo sapiens 13-22 15331178-0 2004 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Docetaxel 123-132 caspase 3 Homo sapiens 65-74 16149076-2 2005 Treatment of HL-60 cells with docetaxel resulted in the production of reactive oxygen species (ROS), activation of caspase-3 (-like) protease, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activation, bcl-2 phosphorylation and apoptosis. Docetaxel 30-39 caspase 3 Homo sapiens 115-141 15566641-0 2004 [Enhancement of FG020326 on sensitivity of MCF-7/ADR cells to taxotere via enhancing activation of caspase-8 and caspase-3]. Docetaxel 62-70 caspase 3 Homo sapiens 113-122 15566641-11 2004 Activities of caspase-3 and caspase-8 in MCF-7/ADR cells cultured with 10 micromol/L FG020326 and 0.1 micromol/L taxotere were increased in a time-dependent manner,and reached peak values at 48 h, which were significantly higher than those in cells cultured with taxotere alone. Docetaxel 113-121 caspase 3 Homo sapiens 14-23 15566641-11 2004 Activities of caspase-3 and caspase-8 in MCF-7/ADR cells cultured with 10 micromol/L FG020326 and 0.1 micromol/L taxotere were increased in a time-dependent manner,and reached peak values at 48 h, which were significantly higher than those in cells cultured with taxotere alone. Docetaxel 263-271 caspase 3 Homo sapiens 14-23 15566641-12 2004 CONCLUSION: FG020326 may reverse drug-resistance of MCF-7/ADR cells towards taxotere through enhancing activation of caspase-8 and caspase-3 induced by taxotere. Docetaxel 152-160 caspase 3 Homo sapiens 131-140 16361572-10 2005 Caspase-3 and caspase-8 activity also increased significantly in docetaxel-treated SKOV3 and HeyA8 cells but not in the taxane-resistant cells. Docetaxel 65-74 caspase 3 Homo sapiens 0-9 16361572-11 2005 DEVD-fmk (caspase-3 blocker) was able to block both FAK cleavage and apoptosis mediated by docetaxel in SKOV3 and HeyA8 cells. Docetaxel 91-100 caspase 3 Homo sapiens 10-19 16361572-14 2005 CONCLUSIONS: Docetaxel induces FAK cleavage, mediated through activation of caspase-3, in taxane-sensitive ovarian cancer cells but not in taxane-resistant cells. Docetaxel 13-22 caspase 3 Homo sapiens 76-85 15492266-6 2004 Ritonavir enhanced the antiproliferative and proapoptotic effects of docetaxel in the hormonally independent DU145 prostate cancer cells in vitro as measured by the clonogenic soft agar assay and detection of the activated form of caspase-3 and cleavage of poly(ADP-ribose) polymerase using Western blot analysis. Docetaxel 69-78 caspase 3 Homo sapiens 231-240 15331178-7 2004 Docetaxel elicited ROS production from NADPH oxidase, which in turn triggered activation of caspase-3, leading to apoptosis in HL-60 cells. Docetaxel 0-9 caspase 3 Homo sapiens 92-101 11992642-0 2002 Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Docetaxel 161-170 caspase 3 Homo sapiens 29-38 15282376-6 2004 Finally, 5-fluorouracil and docetaxel were shown to cause apoptotic cell death involving caspase-3 cleavage in Centre d"Etude du Polymorphisme Humain lymphoblastoid cells. Docetaxel 28-37 caspase 3 Homo sapiens 89-98 12687011-8 2003 As a result, PSK enhanced the docetaxel-induced caspase-3 activation. Docetaxel 30-39 caspase 3 Homo sapiens 48-57 11992642-13 2002 We conclude that docetaxel is able to activate caspase-3, induce Bcl-2 phosphorylation and apoptosis in cells that show a prolonged G2/M arrest, but cells may also die by a caspase-3-independent cell death mechanism. Docetaxel 17-26 caspase 3 Homo sapiens 47-56 11992642-13 2002 We conclude that docetaxel is able to activate caspase-3, induce Bcl-2 phosphorylation and apoptosis in cells that show a prolonged G2/M arrest, but cells may also die by a caspase-3-independent cell death mechanism. Docetaxel 17-26 caspase 3 Homo sapiens 173-182 10699926-10 2000 These results extend to taxol and taxotere the notion that drug-induced apoptosis is delayed upstream of caspase-3 activation in K562 cells, that such kinetics is independent of drug concentration and exposure time, and that it is linked to intrinsic cellular characteristics mapping between bcl-2 phosphorylation and cytochrome c release. Docetaxel 34-42 caspase 3 Homo sapiens 105-114